|Articles|October 11, 2022
- Pharmaceutical Executive-10-01-2022
- Volume 42
- Issue 10
Pharmaceutical Executive, October 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
Healthy Planet, Healthy People: How Pharma Can Lead the Wayover 3 years ago
At the Heart of Pharma: ESG has Arrived as a Central Strategyover 3 years ago
Keeping it Simpleover 3 years ago
All About the Rates: The Fallout of Fed Hikes for Biotechover 3 years ago
Exploring Fixed and Variable Coverage Principlesover 3 years ago
Inclusion Check-In: Who are You Giving Your Energy To?over 3 years ago
Cracking the Code to Commercial Promise in Asiaover 3 years ago
Push for Full Embrace of Digital Care Draws Opposition in Europeover 3 years ago
Seeking Harmonized Testing, Regulation, and ManufacturingNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5

